1Polido -Pereira J, Vieira-Sousa E, Fonseca JE.Rheumatoid arthritis: what is refractory disease and how to manage it[J]. Autoimmun Rev,2011,10( 11 ) :707-713.
5Schellekens GA, Visser H, de jang BAW, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide [J]. Arthritis Rheum,2000,43:155.
6Bizzaro N, Mazzanti G, Tonutti E, et al. Diagnostic accuracy of the anticitndline antibody assay for rheumatoid arthritis[J]. Clinical Chemistry, 2001,47(61) : 1089.
7Amett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 criteria for the classification of rheumatoid arthritis[J]. Arthritis Rheum, 1988,31:315.
8Papadopoulos NG, Tsiaousis GZ, Pavlitou-Tsiontsi A, et al. Does the Presence of Anti-CCP Autoantibodies and Their Serum Levels Influence the Severity and Activity in Rheumatoid Arthritis Patients[J]. Clin Rev Allergy Immunol,2008,34(1) : 11.
9Samanci N,Ozdem S,Akbas H,et al. Diagnostic value and clinical significance of anti-CCP in patients with advanced rheumatoid arthritis[J]. J Natl Med Assoc,2005,97(8) : 1120.
10del Val del Amo N, Ibanez Bosch R, Fito Manteca C, et at. Anti-cyclic citrullinated peptide antibody in rheumatoid arthritis: relation with disease aggressiveness[J] .Clin Exp Rheumatol,2006,24(3):281.
